Focused On-demand Library for RAS guanyl-releasing protein 4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q8TDF6

UPID:

GRP4_HUMAN

Alternative names:

Alternative UPACC:

Q8TDF6; A6H8M4; C0LTP2; C0LTP3; C0LTP4; C0LTP5; C0LTP7; C9J416; C9JHZ1; Q8N858; Q96QN5; Q96QN6; Q96QN7

Background:

RAS guanyl-releasing protein 4 (RASGRP4) is a pivotal mediator in cellular signaling, functioning as a cation- and diacylglycerol (DAG)-regulated nucleotide exchange factor. It plays a crucial role in activating Ras by facilitating the exchange of GDP for GTP, a key step in signal transduction pathways that influence cell differentiation and proliferation.

Therapeutic significance:

Understanding the role of RAS guanyl-releasing protein 4 could open doors to potential therapeutic strategies. Its involvement in mast cells differentiation suggests its potential impact on immune responses and inflammatory diseases, making it a target of interest for drug discovery efforts aimed at modulating immune system functions.